Human Longevity, Inc. Launches Advanced Pancreatic Cancer Test
Human Longevity, Inc. (HLI), a frontrunner in the field of precision health, has recently enhanced its cancer prevention offerings. The company has introduced the ClearNote Health Avantect Pancreatic Cancer Test into its portfolio, designed to assist clients in detecting pancreatic cancer in its early stages. The introduction of this innovative blood test marks a significant development in HLI's commitment to preventative health strategies.
Revolutionizing Cancer Detection
Pancreatic cancer is known for being particularly elusive in its early detection, which is crucial for improving treatment outcomes. By leveraging whole genome sequencing and advanced imaging techniques, Human Longevity can change the landscape of early cancer detection. The Avantect test represents a blend of cutting-edge technology, aiming to identify early signs of pancreatic cancer, ultimately leading to timely interventions.
The Power of Avantect Test
The Avantect test specifically analyzes 5-hydroxymethylcytosine (5hmC) markers in the cell-free DNA collected through a simple blood draw. This test provides an accuracy level of 68.3% sensitivity and 96.9% specificity, making it a reliable tool for identifying at-risk individuals. It is particularly aimed at those who are at a heightened risk for pancreatic cancer, including older adults recently diagnosed with type 2 diabetes.
Enhancing Detection with Advanced Technologies
By combining the Avantect test with HLI's comprehensive whole genome sequencing that evaluates over 3 billion base pairs, the company offers an unparalleled early detection service. The use of enhanced MRI imaging techniques further aids in visualizing pancreatic conditions. This holistic approach positions clients to receive the most thorough cancer testing available.
Aimed at High-Risk Individuals
This groundbreaking test will first be made available to executives and high-profile clients of HLI, many of whom are already engaged in extensive health management programs. Clients with conditions such as new-onset diabetes or a family history of pancreatic cancer will be prioritized.
Human Longevity’s Vision for the Future
The ongoing mission of Human Longevity is to empower individuals with the knowledge and tools necessary for preventing diseases before they manifest into serious health issues. The introduction of the Avantect test underscores this vision, representing a vital step towards realizing proactive health management.
Precision and Proactivity in Healthcare
Dr. Wei-Wu He, the Executive Chairman of Human Longevity, emphasizes the importance of early detection, urging clients to seek solutions that proactively address potential health issues. HLI aims to shift the healthcare paradigm from reactive measures to preemptive strategies, continually enhancing its approaches to client wellness.
Contact Information
For those interested in learning more about the Avantect test and other services offered by Human Longevity, additional information is available on their website.
Frequently Asked Questions
What is the Avantect Pancreatic Cancer Test?
The Avantect test is a new DNA-based blood test designed to detect early-stage pancreatic cancer.
How does the Avantect test improve early cancer detection?
It combines cell-free DNA analysis with advanced imaging techniques to enhance detection capabilities.
Who should consider taking the Avantect test?
The test is aimed at individuals at higher risk, especially those recently diagnosed with type 2 diabetes or with a family history of pancreatic cancer.
What are the accuracy rates of the Avantect test?
The test demonstrates 68.3% sensitivity and 96.9% specificity for early-stage pancreatic cancer.
What is Human Longevity's overall mission?
Human Longevity aims to empower individuals to prevent diseases proactively and enhance longevity through advanced health technologies.
